Metabolism of Apolipoproteins AI and AII in a Patient with Paradoxical Reduction in High-Density Lipoprotein Due to Ciprofibrate

Chandler HA Batchelor AJ . Ciprofibrate and lipid profile. Lancet 1994; 344: 128–9.

Capps NE . Lipid profiles on fibric-acid derivatives. Lancet 1994; 344: 684–5.

McLeod AJ Warren RJ Armitage M . Abnormal lipid profiles on fibrate derivatives. Lancet 1996; 347: 261.

Murphy MJ Packard CJ Oreilly DS . Fibrates and HDL cholesterol. Ann Clin Biochem 1997; 34: 114.

Collinson PO Hjelm CJ Canepaanson R . Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 1996; 33: 159–61.

McLeod AJ Warren RJ Armitage M . Ciprofibrate and lipid profile. Lancet 1994; 344: 955.

Oleesky DA Mir MA . Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Ann Clin Biochem 1997; 34: 573–4.

Elkhalil L Majd Z Bakir R Perez-Mendez O Castro G Poulain P Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism 1997; 46: 474–83.

Barrett PH Bell BM Cobelli C Golde H Schumitzky A Vicini P SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism 1998; 47: 484–92.

Ford GC Cheng KN Halliday D . Analysis of (1-¹³C)leucine and (¹³C)KIC in plasma by capillary gas chromatography/mass spectrometry in protein turnover studies. Biomed Mass Spectrom 1985; 12: 432–6.

Saku K Gartside PS Hynd BA Mendoza SG Kashyap ML . Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism 1985; 34: 754–64.

Le NA Ginsberg HN . Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988; 37: 614–7.

Ikewaki K Rader DJ Schaefer JR Fairwell T Zech LA Brewer HB . Evaluation of apo A-I kinetics in humans using simultaneous stable isotope and exogenous radiotracer methods. J Lipid Res 1993; 34: 2207–15.

Fisher WR Venkatakrishnan V Zech LA Hall CM Kilgore LL Stacpoole PW Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. J Lipid Res 1995; 36: 1618–28.

Malmendier CL Delcroix C . Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial. Atherosclerosis 1985; 55: 161–9.

Kashyap ML Saku K . HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with gemfibrozil. Adv Exp Med Biol 1991; 285: 233–6.

Shepherd J Packard CJ Stewart JM Atmeh RF Clark RS Boag DE Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 1984; 74: 2164–77.